Melanoma Institute Australia posted on LinkedIn:
“Heralded as a cancer treatment revolution, the pre-surgery (neoadjuvant) use of combination immunotherapy looks set to become standard treatment for melanoma, and to impact other cancers across the globe.
Ground-breaking results from the Phase 3 NADINA Clinical Trial, an international collaboration co-led by MIA’s Prof Georgina Long and Prof Christian Blank from The Netherlands Cancer Institute.”